The policy committee decided to approve all six directors recommended by Song Young-sook and Lim Joo-hyeon.
President Joohyun Lim answers questions
(Seoul = Larose.VIP) Reporter Kim Byeong-gyu = The National Pension Service sided with the mother and daughter in the management rights dispute between them over Hanmi Pharmaceutical Group.
The National Pension Fund Fiduciary Responsibility Expert Committee (Fiduciary Committee, Chairman Han Seok-hoon) held a meeting on the 26th to deliberate on the agenda for the regular general shareholders’ meeting of Hanmi Science to be held on the 28th, and to appoint Lim Joo-hyun and Lee Woo-hyun recommended by Hanmi Science’s current management led by Hanmi Group Chairman Song Young-sook. It was decided to agree to the appointment of executive directors, Choi In-young, non-executive director, and outside directors Kim Ha-il, Seo Jeong-mo, and Park Gyeong-jin.
Meanwhile, the committee decided to oppose all proposals for the appointment of executive directors Lim Jong-yoon and Lim Jong-hoon, other non-executive directors Kwon Gyu-chan and Bae Bo-kyung, and outside directors Sabong-gwan proposed by the eldest and second sons of the same family, Lim Jong-yoon, president of Hanmi Pharmaceutical, and Lim Jong-hoon, CEO of Hanmi Fine Chemical. decided.
As a result, Chairman Song Young-sook and Hanmi Science President Lim Joo-hyeon are in an advantageous position in the dispute over Hanmi Science’s management rights. In addition, the integration of Hanmi Pharmaceutical Group and OCI Group, promoted by her mother and daughter, also gained momentum.
Hanmi Science is the holding company of Hanmi Pharmaceutical. The National Pension Service owns a 7.66% stake in Hanmi Science, so it is evaluated as having a casting vote in this management dispute.
bkkim@yna.co.kr
Report to KakaoTalk okjebo
